Kura Oncology Inc (NAS:KURA)
$ 8.86 -0.08 (-0.89%) Market Cap: 688.99 Mil Enterprise Value: 250.32 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 29/100

Kura Oncology Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 25, 2021 / 07:20PM GMT
Release Date Price: $26.88 (-7.79%)
Wei Ji Chang
SVB Leerink LLC, Research Division - MD of Emerging Oncology & Senior Research Analyst

So hello, everyone. Thanks for joining us. My name is Jonathan Chang. I'm part of the SVB Leerink Equity Research Team. It's my pleasure to host the management team of Kura. And we have with us today, President and CEO, Troy Wilson. So thank you very much for joining us. For the investors that are joining us, feel free to submit questions or e-mail them to me at [email protected].

And with that, let's get started. Troy, would you please briefly introduce the company?

Troy Edward Wilson
Kura Oncology, Inc. - Chairman, CEO & President

Sure, Jonathan, and thank you, and thanks to SVB Leerink for the opportunity to participate and to do this virtual fireside chat.

Kura is a precision oncology company focused on developing targeted therapies for the treatment of cancer. We have two programs, KO-539, which is targeting genetically defined subsets of acute leukemia by targeting a protein-protein interaction that is essential for

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot